Zhitong Financial APP learned that$Moderna Inc (MRNA.US) $MRNA-1273.211, the candidate drug for its first bivalent mRNA COVID-19 vaccine enhancer, outperformed the currently licensed COVID-19 vaccine booster MRNA-1273, according to data released Tuesday.
It is reported that MRNA-1273.211 is a candidate vaccine for Beta variants and a wider range of variants. The data showed that 1 month and 6 months after inoculation, the neutralizing antibody titer of 50 μ g MRNA-1273.211 was 2.20 and 2.15 times higher than that of MRNA-1273, respectively, and the candidate vaccine was well tolerated among 300 subjects who received 50 μ g dose and 595 subjects who received 100 μ g dose.
In addition, Moderna Inc is currently promoting a bivalent mRNA COVID-19 vaccine candidate called MRNA-1273.214. MRNA-1273.214 developed a bivalent vaccine for Moderna Inc, which combines the mRNA COVID-19 vaccine MRNA-1273 (Spikevax) for SARS-CoV-2 and the COVID-19 vaccine for Omicron mutant MRNA-1273.529, in order to improve the protective effect of COVID-19 vaccine on the population after receiving COVID-19 vaccine. Preliminary test results are expected to be released in the second quarter of 2022.
St é phane Bancel, CEO of Moderna Inc, said MRNA-1273.214 "remains the main candidate for COVID-19 vaccine boosting in the Northern Hemisphere in the fall of 2022."